11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

Journal of Experimental Medicine

Volumn 202, Issue 4, 2005, Pages 517-527

  Hermanowski Vosatka, Anne ^a   Balkovec, James M ^a   Cheng, Kang ^a   Chen, Howard Y ^a   Hernandez, Melba ^a   Koo, Gloria C ^a   Le Grand, Cheryl B ^a   Li, Zhihua ^a   Metzger, Joseph M ^a   Mundt, Steven S ^a   Noonan, Heather ^a   Nunes, Christian N ^a   Olson, Steven H ^a   Pikounis, Bill ^a   Ren, Ning ^a   Robertson, Nancy ^a   Schaeffer, James M ^a   Shah, Kashmira ^a   Springer, Martin S ^a   Strack, Alison M ^a   Strowski, Matthias ^a,b   Wu, Kenneth ^a   Wu, TsueiJu ^a   Xiao, Jianying ^a   Zhang, Bei B ^a   Wright, Samuel D ^a   Thieringer, Rolf ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; 11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 (1 ADAMANTYL) 6,7,8,9 TETRAHYDRO 5H[1,2,4]TRIAZOLO[4,3 A]AZEPINE; APOLIPOPROTEIN E; CHOLESTEROL; FATTY ACID; GLUCAGON; GLUCOCORTICOID; GLUCOSE; INSULIN; MIFEPRISTONE; OXIDOREDUCTASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 3 (1 ADAMANTYL) 6,7,8,9 TETRAHYDRO 5H (1,2,4)TRIAZOLO(4,3 A)AZEPINE; 3-(1-ADAMANTYL)-6,7,8,9-TETRAHYDRO-5H-(1,2,4)TRIAZOLO(4,3-A)AZEPINE; ADAMANTANE; AZEPINE DERIVATIVE; CORTISONE; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROCORTISONE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DIET RESTRICTION; DISEASE MODEL; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; GLUCOSE TOLERANCE; HORMONE INHIBITION; INHIBITION KINETICS; MALE; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; ARTERIOSCLEROSIS; ATHEROGENIC DIET; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; INSTITUTE FOR CANCER RESEARCH MOUSE; INSULIN RESISTANCE; METABOLISM; MOUSE MUTANT; SYNDROME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADAMANTANE; ANIMALS; AORTA; ARTERIOSCLEROSIS; AZEPINES; BLOOD GLUCOSE; CORTISONE; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FATTY ACIDS; HYDROCORTISONE; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; SYNDROME; TRIAZOLES; TRIGLYCERIDES;

EID: 23944493717     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20050119     Document Type: Article

References (53)

1. Agarwal, A.K., C. Monder, B. Eckstein, and P.C. White. 1989. Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J. Biol. Chem. 264:18939-18943.
2. Albiston, A.L., V.R. Obeyesekere, R.E. Smith, and Z.S. Krozowski. 1994. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 105:R11-R17.
3. Walker, B.R., and J.R. Seckl. 2003. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Ther. Targets. 7:771-783.
4. Masuzaki, H., and J.S. Flier. 2003. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)-a promising drug target for the treatment of metabolic syndrome. Curr. Drug Targets Immune Endocr. Metabol. Disord. 3:255-262.
5. Stewart, P.M. 2003. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur. J. Endocrinol. 149:163-168.
6. Masuzaki, H., J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J.S. Flier. 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science. 294:2166-2170.
7. Masuzaki, H., H. Yamamoto, C.J. Kenyon, J.K. Elmquist, N.M. Morton, J.M. Paterson, H. Shinyama, M.G. Sharp, S. Fleming, J.J. Mullins, et al. 2003. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112:83-90.
8. Kotelevtsev, Y., M.C. Holmes, A. Burchell, P.M. Houston, D. Schmoll, P. Jamieson, R. Best, R. Brown, C.R. Edwards, J.R. Seckl, and J.J. Mullins. 1997. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA. 94:14924-14929.
9. Kotelevtsev, Y., R.W. Brown, S. Fleming, C. Kenyon, C.R. Edwards, J.R. Seckl, and J.J. Mullins. 1999. Hypertension in mice lacking 11beta- hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103:683-689.
10. Luo, J., J. Quan, J. Tsai, C.K. Hobensack, C. Sullivan, R. Hector, and G.M. Reaven. 1998. Nongenetic mouse models of non-insulindependent diabetes mellitus. Metabolism. 47:663-668.
11. Zhang, S.H., R.L. Reddick, J.A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
12. Plump, A.S., J.D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
13. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 285:2486-2497.
14. Ford, E.S., W.H. Giles, and W.H. Dietz. 2002. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287:356-359.
15. Palaniappan, L., M.R. Carnethon, Y. Wang, A.J. Hanley, S.P. Fortmann, S.M. Haffner, and L. Wagenknecht. 2004. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 27:788-793.
16. Bujalska, I.J., S. Kumar, and P.M. Stewart. 1997. Does central obesity reflect "Cushing's disease of the omentum"? Lancet. 349:1210-1213.
17. Rask, E., T. Olsson, S. Soderberg, R. Andrew, D.E. Livingstone, O. Johnson, and B.R. Walker. 2001. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 86:1418-1421.
18. Rask, E., B.R. Walker, S. Soderberg, D.E. Livingstone, M. Eliasson, O. Johnson, R. Andrew, and T. Olsson. 2002. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87:3330-3336.
19. Paulmyer-Lacroix, O., S. Boullu, C. Oliver, M.C. Alessi, and M. Grino. 2002. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J. Clin. Endocrinol. Metab. 87:2701-2705.
20. Whorwood, C.B., S.J. Donovan, D. Flanagan, D.I. Phillips, and C.D. Byrne. 2002. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes. 51:1066-1075.
21. Livingstone, D.E., and B.R. Walker. 2003. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J. Pharmacol. Exp. Ther. 305:167-172.
22. Alberts, P., L. Engblom, N. Edling, M. Forsgren, G. Klingstrom, C. Larsson, Y. Ronquist-Nii, B. Ohman, and L. Abrahmsen. 2002. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 45:1528-1532.
23. Alberts, P., C. Nilsson, G. Selen, L.O. Engblom, N.H. Edling, S. Norling, G. Klingstrom, C. Larsson, M. Forsgren, M. Ashkzari, et al. 2003. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 144:4755-4762.
24. Abate, N., and A. Garg. 1995. Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog. Lipid Res. 34:53-70.
25. Engeli, S., J. Bohnke, M. Feldpausch, K. Gorzelniak, U. Heintze, J. Janke, F.C. Luft, and A.M. Sharma. 2004. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 12:9-17.
26. Westerbacka, J., H. Yki-Jarvinen, S. Vehkavaara, A.M. Hakkinen, R. Andrew, D.J. Wake, J.R. Seckl, and B.R. Walker. 2003. Body fat distribution and cortisol metabolism in healthy men: enhanced 5betareductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J. Clin. Endocrinol. Metab. 88:4924-4931.
27. Tomlinson, J.W., B. Sinha, I. Bujalska, M. Hewison, and P.M. Stewart. 2002. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 87:5630-5635.
28. Davani, B., A. Khan, M. Hult, E. Martensson, S. Okret, S. Efendic, H. Jornvall, and U.C. Oppermann. 2000. Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J. Biol. Chem. 275:34841-34844.
29. Ogawa, A., J.H. Johnson, M. Ohneda, C.T. McAllister, L. Inman, T. Alam, and R.H. Unger. 1992. Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J. Clin. Invest. 90:497-504.
30. Duplomb, L., Y. Lee, M.Y. Wang, B.H. Park, K. Takaishi, A.K. Agarwal, and R.H. Unger. 2004. Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. Biochem. Biophys. Res. Commun. 313:594-599.
31. Shimomura, Y., G.A. Bray, and M. Lee. 1987. Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm. Metab. Res. 19:295-299.
32. Spear, G.S., K. Ohshima, G.A. Bray, and M.V. Caple. 1986. Effect of adrenalectomy on the pancreas of db/db mice. Horm. Metab. Res. 18:743-745.
33. Friedman, J.E., Y. Sun, T. Ishizuka, C.J. Farrell, S.E. McCormack, L.M. Herron, P. Hakimi, P. Lechner, and J.S. Yun. 1997. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J. Biol. Chem. 272:31475-31481.
34. Berger, J., M. Tanen, A. Elbrecht, A. Hermanowski-Vosatka, D.E. Moller, S.D. Wright, and R. Thieringer. 2001. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J. Biol. Chem. 276:12629-12635.
35. Morton, N.M., M.C. Holmes, C. Fievet, B. Staels, A. Tailleux, J.J. Mullins, and J.R. Seckl. 2001. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276:41293-41300.
36. Hermanowski-Vosatka, A., D. Gerhold, S.S. Mundt, V.A. Loving, M. Lu, Y. Chen, A. Elbrecht, M. Wu, T. Doebber, L. Kelly, et al. 2000. PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver. Biochem. Biophys. Res. Commun. 279:330-336.
37. Trevisan, M., J. Liu, F.B. Bahsas, and A. Menotti. 1998. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am. J. Epidemiol. 148:958-966.
38. Wilson, P.W., W.B. Kannel, H. Silbershatz, and R.B. D'Agostino. 1999. Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med. 159:1104-1109.
39. Thieringer, R., C.B. Le Grand, L. Carbin, T.Q. Cai, B. Wong, S.D. Wright, and A. Hermanowski-Vosatka. 2001. 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 167:30-35.
40. Cai, T.Q., B. Wong, S.S. Mundt, R. Thieringer, S.D. Wright, and A. Hermanowski-Vosatka. 2001. Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not 2 in human aortic smooth muscle cells by inflammatory stimuli. J. Steroid Biochem. Mol. Biol. 77:117-122.
41. Brem, A.S., R.B. Bina, T.C. King, and D.J. Morris. 1998. Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension. 31:459-462.
42. Souness, G.W., A.S. Brem, and D.J. Morris. 2002. 11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids. 67:195-201.
43. Faggiano, A., R. Pivonello, S. Spiezia, M.C. De Martino, M. Filippella, C. Di Somma, G. Lombardi, and A. Colao. 2003. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88:2527-2533.
44. Sapolsky, R.M., L.M. Romero, and A.U. Munck. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21:55-89.
45. Yeager, M.P., P.M. Guyre, and A.U. Munck. 2004. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol. Scand. 48:799-813.
46. Dhabhar, F.S., and B.S. McEwen. 1999. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc. Natl. Acad. Sci. USA. 96:1059-1064.
47. Galon, J., D. Franchimont, N. Hiroi, G. Frey, A. Boettner, M. Ehrhart-Bornstein, J.J. O'Shea, G.P. Chrousos, and S.R. Bornstein. 2002. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16:61-71.
48. Assmann, G., and H. Schulte. 1988. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart J. 116:1713-1724.
49. Kumari, M., C. Grahame-Clarke, N. Shanks, M. Marmot, S. Lightman, and P. Vallance. 2003. Chronic stress accelerates atherosclerosis in the apolipoprotein E deficient mouse. Stress. 6:297-299.
50. Yau, J.L., J. Noble, C.J. Kenyon, C. Hibberd, Y. Kotelevtsev, J.J. Mullins, and J.R. Seckl. 2001. Lack of tissue glucocorticoid reactivation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc. Natl. Acad. Sci. USA. 98:4716-4721.
51. Nosadini, R., S. Del Prato, A. Tiengo, A. Valerio, M. Muggeo, G. Opocher, F. Mantero, E. Duner, C. Marescotti, F. Mollo, and F. Belloni. 1983. Insulin resistance in Cushing's syndrome. J. Clin. Endocrinol. Metab. 57:529-536.
52. Page, R., M. Boolell, A. Kalfas, S. Sawyer, R. Pestell, G. Ward, and F. Alford. 1991. Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in Cushing's disease: a minimal model analysis. Clin. Endocrinol. (Oxf.). 35:509-517.
53. Sparrow, C.P., C.A. Burton, M. Hernandez, S. Mundt, H. Hassing, S. Patel, R. Rosa, A. Hermanowski-Vosatka, P.R. Wang, D. Zhang, et al. 2001. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21:115-121.